Artículo
Innate immune sensing of cancer: clues from an identified role for type I IFNs
Fecha de publicación:
06/2012
Editorial:
Springer
Revista:
Cancer Immunology Immunotherapy
ISSN:
0340-7004
e-ISSN:
1432-0851
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
A subset of patients with a variety of cancers shows evidence of a natural adaptive immune response against their tumor, as evidenced by spontaneous T-cell infiltration, circulating anti-tumor T cells, or antibody responses. Evidence has indicated that such natural immune responses have positive prognostic import in early stage disease and may be predictive of clinical response to immunotherapeutics in advanced disease. However, these observations raise a new critical fundamental question?what innate immune signals might be generated in the context of non-pathogen-induced cancers that drive productive antigen presentation toward induction of an adaptive immune response? Gene expression profiling in melanoma revealed that tumors having high expression of T-cell markers also show evidence of a type I IFN transcriptional signature. Mechanistic experiments in mice have revealed that a spontaneous CD8+ T-cell response against transplantable tumors depends on host type I IFN signaling, through a mechanism dependent upon CD8α+ dendritic cells (DCs). The requirement for type I IFN production by host DCs has suggested a subset of innate immune sensing receptors and signaling pathways that might be involved with initiating this process. Elucidating further these innate immune mechanisms should provide new insights into cancer immunotherapy.
Palabras clave:
Cancer
,
Linfocitos T Cd8
,
Interferon
,
Celulas Dendriticas
,
Tumor Immunity
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(IBYME)
Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Gajewski, Thomas F.; Fuertes, Mercedes Beatriz; Woo, Seng Ryong; Innate immune sensing of cancer: clues from an identified role for type I IFNs; Springer; Cancer Immunology Immunotherapy; 61; 8; 6-2012; 1343-1347
Compartir
Altmétricas